InvVax
InvVax is dedicated to developing next-generation vaccines, starting with influenza, using proprietary and novel solutions. Their patented approach targets invariant regions of viruses to prevent pandemics and improve vaccine effectiveness.
Industries
Nr. of Employees
small (1-50)
InvVax
Pasadena Bioscience Collaborative, 2265 E Foothill Blvd, Pasadena, CA 91107
Patents
Products
Epitope-based universal influenza vaccine candidate
A vaccine candidate composed of selected invariant peptide epitopes discovered via functional mapping, tested as adenoviral-vectored and peptide constructs in preclinical models.
Epitope-based universal influenza vaccine candidate
A vaccine candidate composed of selected invariant peptide epitopes discovered via functional mapping, tested as adenoviral-vectored and peptide constructs in preclinical models.
Services
Experimental and computational mapping service that identifies invariant peptide regions on viral proteins using deep mutational scanning and NGS-based functional selection.
Design, construct and preclinical evaluation of epitope-based vaccine candidates, including adenoviral vector production, immunogenicity assays, and animal challenge studies.
Experimental and computational mapping service that identifies invariant peptide regions on viral proteins using deep mutational scanning and NGS-based functional selection.
Design, construct and preclinical evaluation of epitope-based vaccine candidates, including adenoviral vector production, immunogenicity assays, and animal challenge studies.
Expertise Areas
- Universal influenza vaccine development
- Deep mutational scanning and functional genomics
- Epitope-based vaccine design
- Preclinical vaccine evaluation (mouse and ferret challenge models)
Key Technologies
- Deep mutational scanning
- Next-generation sequencing with molecular barcoding
- Computational variance scoring (variance quotient)
- Epitope mapping and selection